Background: In cancer patients, correlation between response to chemotherapy and gain in survival remains debated. We addressed this question in a multivariate analysis evaluating response to chemotherapy as a factor influencing survival of patients with metastatic breast cancer.
Introduction
Although the management of metastatic breast cancer has been improved during the last two decades, chemotherapy remains palliative. It is generally accepted that virtually all metastatic breast cancer patients are destined to die of their disease within a relatively short time, even if systemic chemotherapy or endocrine therapies induce substantial and durable objective tumour responses. However, a small fraction of metastatic breast cancer patients can achieve long-term survival after systemic therapies [1] , Assessment of the relationship between response to treatment and the patient's ultimate outcome is a central preoccupation in clinical research. The efficacy of an investigational treatment could be evaluated more rapidly through its effect upon response rather than through its effect upon survival. But it remains to be proven that the patient who achieves a response could benefit from treatment in terms of survival expectancy [2] . Response may also represent a marker of underlying favourable characteristics correlated with better survival. Patients experiencing objective response may be those patients fated to have the longest natural disease history. If so the response to treatment cannot add new information to other known prognostic factors. Numerous previous studies have examined the prognostic value of individual factors in recurrent breast cancer. Similarly, survival of patients with metastatic breast cancer can be likewise predicted using several prognostic factors at the time of initial diagnosis of metastatic disease. Parameters such as prior adjuvant chemotherapy, oestrogen receptor status and dominant sites of recurrence are well-documented with regard to influence on survival [3] [4] [5] [6] [7] [8] . Characteristics of responders have also been defined in large series [9, 10] . The aim of our study was to assess the influence of response to treatment as an independent prognostic factor for survival in metastatic breast cancer patients.
Patients and methods

Patients
Between 1977 and 1992. the department of medical oncology of the Institut Curie initiated eight consecutive protocols based on first-line doxorubicin-containing chemotherapy in metastatic breast cancer. All data were prospectively collected and entered into a centralised Patient Data Management System. The data were last updated in mid-1998. The median follow-up time is 13 years (155 months). A total of 1430 patients with metastatic breast cancer were analysed for this study. Patients had to be above 18 years of age and to have histologically confirmed carcinoma of the breast, metastatic disease with lesions that could be evaluated. Patients who had received prior chemotherapy for metastatic disease were excluded. Patients were ineligible if they had a granulocyte count of less than 1.5 x 10 9 per litre or a platelet count of less than 100 x 10 9 per litre, unless myelosuppression was due to bone marrow involvement. Patients were also excluded if they had a bilirubin level > 1.5 normal, a history of congestive heart failure or had brain metastases as the only evidence of tumour spreading. Patients were allowed to undergo concurrent irradiation provided they had assessable or measurable disease outside the field of irradiation.
Registered characteristics of primary disease were clinical tumour and nodal status (TNM), SBR grade, oestrogen receptor status, initial surgery, adjuvant radiotherapy, adjuvant chemotherapy and adjuvant hormonotherapy. Clinical and biological characteristics collected at time of recruitment were age, performance status (Karnofsky index), weight loss immediately prior to treatment, menopausal status, diseasefree interval (DFI) from primary tumour diagnosis to metastases, year of inclusion in a metastatic trial, number of sites and location of metastases, serum lactic dehydrogenase (LDH), serum alkaline phosphatase, yGT, AST, serum albumin levels and absolute lymphocyte counts. Summaries of all parameters are given in Tables 2 and 3 . Tumour status (T) was not prospectively registered before 1985 and is available only in 59% of the patients.
Response to chemotherapy was assessed at 4, 8 and 12 months after starting treatment. Standard International Union Against Cancer (UICC) criteria to determine responses to therapy were used [12] . Response at 4, 8 and 12 months as well as maximal response achieved within 12 months were analysed Complete response (CR) was defined as the complete disappearance of clinical and laboratory evidence of disease for a minimum of eight weeks. In the case of osseous metastases, CR required disappearance of pain in known tumour sites plus evidence of recalcification of osteolytic metastases on X-ray. Partial response (PR) was defined as at least a 50% decrease of all bidimensionally measurable lesions Objective response was defined by the achievement of a complete or a partial response. Progressive disease (PD) was defined as the development of any new lesions, including central nervous system metastases or reactivation of previously diseased areas. Stable disease (SD) was defined as the absence of tumour progression or objective response.
Statistical methods
For categorical variables, initial statistical comparisons were made by Pearson % 2 test. For quantitative variables Student's r-test was used. Survival time was measured from the date of entry in the study to the date of death or last follow-up. Survival curves were estimated using the Kaplan Meier estimates and compared using the log-rank test [13, 14] . Patients experiencing early death (before four months) were not 
Results
Response could be assessed in 1426 out of 1430 patients included in 8 chemotherapy trials. Overall survival was 24 months from the date of randomisation in a first-line chemotherapy trial and was 30 months from the date of diagnosis of first metastasis. In univariate analysis, classical prognostic factors were found including initial tumour characteristics (axillary lymph node status, presence of hormonal receptors), the interval between initial diagnosis and relapse (DFI), age at relapse, the nature of involved sites (visceral, bone or soft tissues), enzymatic disorder like LDH elevation and the number of metastatic sites. Prior adjuvant chemotherapy was also found to be significantly associated with poor survival (Tables 2 and 3) .
Objective response rate, or best observed response before 12 months, was 63.6% while a total of 249 (17%) patients achieved a complete response. Median survival time and probability of survival at 5 and 10 years were, respectively: 43 months, 35%, 15% (CR); 29 months, 18%, 6% (PR); 18 months, 7%, 2% (SD); 5 months. 0.5%, 0% (PD) ( Table 4 and Figure 1 ).
Survival as a function of response status at either four months (Figure 2 ) or at eight months ( Figure 3 ) follows a similar pattern but when we tested for the quality of response (timing of onset and duration), grossly two populations could be distinguished. Patients who achieved an objective response at four months (early response) and who were still registered as responders at eight months (prolonged response) had the best survival ( Figure 4 ). Patients with a delayed response, i.e., registered at the first time at eight months had a survival comparable to the first group. Early responder patients (four months) but with an early progressive disease (eight months) have a very poor prognosis comparable to patients who never responded to first-line chemotherapy. Both patient groups who had either an early and durable response or a delayed onset of response fared significantly better than patients who had an early but shortened response or no response at all. 203 (14) 79 (6) 238 (17) In a multivariate analysis testing parameters associated with a prolonged survival, response to chemotherapy was the dominant factor followed by normal LDH level, by absence of prior adjuvant chemotherapy, low number of metastatic sites, by prolonged DFI, by high Karnofsky index and by absence of liver metastasis. Patients who had achieved a CR fared better than those with PR, who fared better than SD and better than PD. Even for patients who had prolonged stable disease, i.e., SD at eight months, survival was poorer than for responders. No difference was seen when these same parameters were analysed as a function of the time of response: at four months, at eight months or the best observed response ( Table 5 ). The multivariate analysis confirmed that the time to the first observation of response did not influence the duration of survival (four or eight months).
Conversely, duration of response was a major prognostic factor. The duration of response was significantly correlated with the DFI, defined as time between initial diagnosis and metastatic disease, as shown in Table 7 (P <0.01). Patients with DFI between 6 and 12 months were the poorest responders at 4 and 8 months (34 and 32%, respectively). Patients with DFI between 12 and 24 months had normal RR at 4 months (47%) and poor RR at 8 months (31%) due to early progressive disease. Patients with DFI below six months were mostly patients with metastatic disease at initial diagnosis and were used as reference for statistical tests. Response duration was 7 months for patients with DFI between 6 and 24 months. The detection of metastatic disease after a DFI of more than 2 years resulted in a median delay to a new progression of 14 months.
Discussion
Clinicians know from experience that the patients who respond to treatment fare better than those who do not. It is also to be expected that low response rates and short survival times are observed in studies predominantly accruing patients with very advanced disease and poor general condition, whereas the reverse is true for studies accruing patients with limited disease and in good general condition [16] . The question we asked, therefore, was the response the dominant parameter in this relationship and which other factors were determinant for outcome? More than 35 variables have been assessed in a univariate analysis with included parameters reportedly associated with response such as young age, premenopausal status, low tumour burden and better performance status [9, 10] . In a proportional hazards model these variables were considered covariate (rather than stratification factors). In this model response remained a powerful predictor of survival and could not be explained by either lengthbiased sampling or by other confounding variables.
In our opinion, a misleading way of assessing the relationship between response and survival consists of plotting response rates of several studies against sum-mary statistic on survival, such as median survival, and of fitting a regression line through these points [16, 17] . In the present study regression analysis was performed on individual patient observations since all the data had been prospectively registered in a large series treated in the same institution, and were therefore less subjected to bias.
Comparison of survival by response may also be biased since patients need to live long enough to enjoy a response to treatment. Patients who die early, before they have had a chance to respond to treatment have a major impact upon the survival estimates of the group of patients classified as non-responders. Mantel pointed out that responders may outlive non-responders even with a treatment that worsened survival [18] . It was therefore potentially misleading to estimate the survival distribution separately for patients who had a response to treatment and for the non-responders. For the present analysis, patients were classified into four groups: CR, PR, SD and PD. The presence of guarantee-time bias can be eliminated by setting the time origin for survival after a landmark period long enough for all responses to have been observed [16] . In our study, response was assessed at 4, 8 and 12 months. By taking into account early response at four months and late responses at eight months we have shown that responders (CR and PR) did better than patients with stable disease and obviously than patients with progressive disease. Among the responders, complete responders had a better survival than partial responders.
For the purpose of publication, an explicit policy adopted by most cancer journals is to reject comparisons of survival by response [19] . Similarly the Food and Drug Administration does not accept a survival advantage in responders as evidence of a true drug benefit, because the capacity to respond (rather than response itself) may be the cause of the better survival [20] . The capacity to respond to chemotherapy could be an intrinsic property of a tumour or be related to unknown prognostic factors for survival like biologic markers that were not assessed in this study, for example c-erbB-2, S phase, MDR1 etc. Complete response to first-line chemotherapy has been shown to be an important predictor for a response to second-line chemotherapy [21, 22] . The time from initial diagnosis to the appearance of recurrence, i.e., the DFI is an important prognostic factor that reflects the growth rate of disease. It has proven to be one of the most reliable factors to assess the behaviour of the disease [3, 8, 23] . Nevertheless, when we studied observed response to chemotherapy, we observed a significant relation between DFI and response rate suggesting an influence of kinetic of response according to DFI. The shorter the DFI, the shorter was the response duration. So, for survival tumour growth kinetic is an independent prognostic factor but in a multivariate analysis, this factor was not more predictive of response.
Response to treatment could be a clinically useful indicator of the patient's prognosis, and assessing the degree and rapidity of response is often essential to adjust therapy to the needs of individual patients. Response can be used as a surrogate marker in lieu of survival in testing new treatments. This is one of the applications of neoadjuvant chemotherapy in order to determine sensitivity of the disease to chemotherapy [24, 25] . But, in our study, survival was not related to precocity of observation of response. Prognosis was the same if response was observed at four or eight months after the randomisation. Patients with prolonged response had a similar survival length to patients with delayed response. Conversely, responder patients with an early progressive disease had a very poor prognosis. Short responses with rapid regrowth of tumour will result in death at essentially the same time as if the response had not occurred.
It has been reported for other solid tumours like colon cancer [2] or brain tumours (26) that the failure to demonstrate an objective response (i.e., stable disease) does not necessarily mean the treatment has been ineffective. Stable patients may enjoy a prolonged survival comparable to responders. However, we have also shown that the clinical relevance of stable disease in breast cancer is poor. Survival duration of this subpopulation is much lower than in responding patients: 18 months versus 29 and 43 months. Unfortunately, in most solid tumours even high objective response rates have only been translated into weeks or months (not years) of improved survival. New agents like docetaxel added to anthracyclines have recently shown increase response rate in MBC and their impact in time to progression are proven [27] . Their influence on survival are expected but should be minimal.
The separation of responders from progressing patients after first-line chemotherapy could allow the selection of a more homogeneous subgroup in which further treatment strategies might achieve a better control of the disease. Specific strategies of maintenance therapy have been tested in complete responders after induction chemotherapy. Treatment like chemotherapy with CMF significantly increased time to relapse time but failed to prolong survival [28] . Other investigators have evaluated the effect of the maintenance endocrine therapy in improving response rate and overall survival [29] . High dose therapy has been proposed in many metastatic breast cancer patients. The selection process appears to have significant impact on the outcome of patients in HDCT trials compared to historical controls [30] . A recent report of randomised trial in MBC of HDCT failed to find any difference but a benefit cannot be completely excluded for the population of complete responders [31] .
In conclusion, our study has shown that response to an anthracycline-based chemotherapy seems to be a potent and independent predictor of survival in patients with advanced breast cancer. This response could add to the known prognostic factors for survival reported in major contributions to the literature. Response is merely a marker of unknown clinical or biological parameters that should be determined. This study could add an argument to the controversial issue of the rapid evaluation of an investigational treatment through its effect upon responses in metastatic breast cancer before achieving effect on survival. Prolonged survival can be achieved in patients with complete response justifying research for specific remission consolidation strategies.
